{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:40:08Z","timestamp":1761568808570,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clgc.2016.05.019","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T21:00:06Z","timestamp":1464469206000},"page":"e145-e150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Matti","family":"Annala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.05.019_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2016.05.019_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clgc.2016.05.019_bib3","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase-deficient kidney cancer\u2013targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.05.019_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1078-0432.CCR-13-2993","article-title":"New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease","volume":"21","author":"Srinivasan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.05.019_bib5","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1038\/ncomms7336","article-title":"Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution","volume":"6","author":"Kovac","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2016.05.019_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2016.05.019_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.05.019_bib8","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","article-title":"Multilevel genomics-based taxonomy of renal cell carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.clgc.2016.05.019_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2016.05.019_bib10","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.05.019_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.05.019_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0959-8049(14)70131-5","article-title":"5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib","volume":"50","author":"Srinivasan","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.05.019_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.MCT-14-0208","article-title":"Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications","volume":"14","author":"Adelaiye","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.05.019_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2016.05.019_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.clgc.2016.05.019_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/2159-8290.CD-14-0380","article-title":"Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy","volume":"4","author":"Al-Ahmadie","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2016.05.019_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ng.3284","article-title":"Germline RECQL mutations are associated with breast cancer susceptibility","volume":"47","author":"Cybulski","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2016.05.019_bib18","doi-asserted-by":"crossref","first-page":"e1005228","DOI":"10.1371\/journal.pgen.1005228","article-title":"Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer","volume":"11","author":"Sun","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.clgc.2016.05.019_bib19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cell.2012.04.033","article-title":"Inhibition of basal FGF receptor signaling by dimeric Grb2","volume":"149","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2016.05.019_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/363085a0","article-title":"Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling","volume":"363","author":"Li","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2016.05.019_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/363083a0","article-title":"The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1","volume":"363","author":"Rozakis-Adcock","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2016.05.019_bib22","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.1407909111","article-title":"Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer","volume":"111","author":"Kiiski","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2016.05.019_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.05.019_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2011.37.2516","article-title":"Complete remission with tyrosine kinase inhibitors in renal cell carcinoma","volume":"30","author":"Albiges","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.05.019_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.05.019_bib26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non\u2013clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.05.019_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10637-010-9491-6","article-title":"Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma","volume":"30","author":"Molina","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2016.05.019_bib28","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.5489\/cuaj.2264","article-title":"Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): case report and review of the literature","volume":"9","author":"de Velasco","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2016.05.019_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10689-011-9491-5","article-title":"Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance","volume":"11","author":"van Spaendonck-Zwarts","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clgc.2016.05.019_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2041-9414-4-5","article-title":"Tumor hypoxia as a driving force in genetic instability","volume":"4","author":"Luoto","year":"2013","journal-title":"Genome Integr"},{"key":"10.1016\/j.clgc.2016.05.019_bib31","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1158\/1078-0432.CCR-10-0286","article-title":"Targeting hypoxic cells through the DNA damage response","volume":"16","author":"Olcina","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.05.019_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/0008-5472.CAN-09-2715","article-title":"Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability","volume":"70","author":"Pires","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2016.05.019_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nsmb.2501","article-title":"Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition","volume":"20","author":"Berti","year":"2013","journal-title":"Nat Struct Mol Biol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:54Z","timestamp":1761564414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316301458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1558767316301458"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.05.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}